drugset
drugset / Trial / NCT05215912

A Single and Multiple Dosing Study Targeting Biparatopic Antibody CD38 in Healthy Volunteers

NCT05215912 ↗

Phase 1 Completed 31 enrolled TeneoFour Inc. Novotech (Australia) Pty Limited · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase 1, Double blind, Single ascending and Multiple ascending dose (SAD and MAD) escalation study in Healthy Volunteers.

Timeline

Start
2022-04-21
Primary completion
2023-05-04
Completion
2023-07-11

Drugs

EvaluationDrugModalityDoseRoute
Subject TNB-738 Unknown — —

Indications

No indication recorded.